Hemogenyx Pharmaceuticals PLC Announces FDA Consents to Phase I Trials of HEMO-CAR-T

February 9, 2024 2:00 AM

FDA Consents to Phase I Trials of HEMO-CAR-TLONDON, UK / ACCESSWIRE / February 9, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has been informed by the U.S. Federal Food and Drug Administration ("FDA") that it has lifted the clinical hold on the Investigational New Drug (IND) application for HEMO-CAR-T for the treatment of acute myeloid leukemia ("AML"). The FDA confirmed that the Company had addressed all...

Read more

Tryp Therapeutics Obtains Interim Order for Plan of Arrangement and Provides Details of Shareholder Meeting

February 8, 2024 4:00 PM

KELOWNA, BC / ACCESSWIRE / February 8, 2024 / Tryp Therapeutics, Inc. ("Tryp" or the "Company") (CSE:TRYP)(OTCQB:TRYPF), a pioneering clinical-stage biotechnology company focused on developing intravenous-infused psilocin (the active metabolite of psilocybin) for diseases with high unmet medical needs, today announced that further to its press releases of December 11, 2023 and January 26, 2024, Tryp has obtained an interim order (the "Interim...

Read more

AmplifyBio CEO J. Kelly Ganjei Discusses Solutions for Reducing Costs and Risk in Advanced Therapy Manufacturing During Fireside Chat at Advanced Therapies Week

February 8, 2024 7:00 AM

NEW ALBANY, OH / ACCESSWIRE / February 8, 2024 / J. Kelly Ganjei, CEO of AmplifyBio, recently participated in a fireside chat panel at Advanced Therapies Week, a conference event in Miami hosted by the Phacilitate event group that brings together thought leaders in cell and gene therapy development for education, collaboration, and networking opportunities, where he shared insights into the intricacies of advanced therapy manufacturing, drawing...

Read more

TuHURA Biosciences, Inc. Appoints Dennis Yamashita, Ph.D., as Chief Scientific Officer and Head of Discovery Research and Early Development

February 7, 2024 10:00 AM

Brings over 30 years of experience in R&D drug discovery and development with a proven track record, including co-inventing Olinvyk (oliceridine), an FDA-approved Mu opioid G-protein biased ligand for treating post-surgical painDr. Yamashita to focus on advancing the Company's novel personalized cancer vaccines to overcome tumor resistance to immunotherapies like checkpoint inhibitors and first-in-class bi-functional antibody drug conjugates...

Read more

Phoreus Biotech Appoints David Schaefer as CEO to Lead Development of Innovative Drug Delivery Nanocarriers

February 7, 2024 8:00 AM

OLATHE, KS / ACCESSWIRE / February 7, 2024 / Phoreus Biotech, an innovator in peptide nanocarriers for drug and vaccine delivery, is proud to announce the appointment of David Schaefer as its new Chief Executive Officer. With more than 25 years of experience in commercial healthcare management, biotechnology, and strategic development, Schaefer brings a wealth of knowledge and expertise to the company."Phoreus Biotech is at the cutting edge of...

Read more

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

February 6, 2024 10:00 AM

Researchers at the BioMed X Institute and the Universitätsmedizin Mannheim just published the results of their collaboration around a new neoepitope vaccine in diffuse midline glioma in Science Advances.HEIDELBERG, GERMANY / ACCESSWIRE / February 6, 2024 / BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances. The work is based on a...

Read more

Cantabio Pharmaceuticals Awarded Major Grant from The Michael J. Fox Foundation for the Development of a Novel DJ-1 Protein Replacement Therapy for the Treatment of Parkinson’s Disease

February 6, 2024 10:00 AM

Grant enables the further development of Cantabio's innovative DJ-1 replacement therapy, which have high therapeutic potential in both disease-modifying and preventive contexts for the treatment of Parkinson's disease.SAN MATEO, CA / ACCESSWIRE / February 6, 2024 / Cantabio Pharmaceuticals, Inc. ("Cantabio" or the "Company"), a preclinical stage pharmaceutical company developing disease-modifying therapeutics and diagnostics for Parkinson's...

Read more

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

February 6, 2024 7:00 AM

NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on...

Read more

Roquefort Therapeutics PLC Announces Operations Update

February 6, 2024 2:00 AM

LONDON, UK / ACCESSWIRE / February 6, 2024 / Roquefort Therapeutics (LSE:ROQ)(OTCQB:ROQAF), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth oncology market, provides an update on its pre-clinical drug development programs, Randox licencing agreement and out-licencing discussions.Pre-Clinical Drug Development ProgramsFurther to the Company's announcement on 6 November 2023,...

Read more

MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value

February 5, 2024 5:15 PM

Tafasitamab sold to IncyteNovartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of € 68.00 per share in cashShareholders benefit from attractive premium of 94 percent to the one-month volume weighted average price before January 25, 2024Novartis provides ample resources to maximize and accelerate pelabresib's potential on a global scaleMorphoSys' Management Board and Supervisory Board unanimously support both...

Read more

ARRALYZE(R) Launches CellShepherd(R): A Fully Autonomous Single-Cell Platform For Real-Time Monitoring Of Functional Assays

February 5, 2024 8:30 AM

GARBSEN, GERMANY / ACCESSWIRE / February 5, 2024 / ARRALYZE®, the Life Science arm of LPKF Laser & Electronics SE, proudly announces the commercial availability of the CellShepherd®. After a successful beta-testing phase in 2023, this groundbreaking platform is now ready to revolutionize cell-based research and development across biomedical and various life science fields.CellShepherd®: Redefining Single-Cell AnalysisCellShepherd®, developed by...

Read more

Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis

February 5, 2024 8:30 AM

Phase 1 clinical trial dosing of first patient complete; primary objective to assess safety/tolerability and absolute bioavailability of TH104Phase 1 study expected to be completed in 1Q24 with topline readout in 2Q24Company fully funded into 2025 with full readouts of Phase 1 and 2 in moderate-to-severe chronic pruritus in PBC expected in 4Q24/1Q25BRIDGEWATER, NJ / ACCESSWIRE / February 5, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune" or...

Read more

WallabyPhenox Boldly Sets New Benchmark in Evidence-Based Medicine With the PROST Trial

February 5, 2024 8:00 AM

PROST Stroke Trial Results Published in JAMA NeurologyIRVINE, CA / ACCESSWIRE / February 5, 2024 / WallabyPhenox, a global pioneer in stroke healthcare innovation, has announced the publication of PROST in JAMA Neurology. Visit JAMA Neurology to view the publication. Commenced in 2019, this clinical study marks a significant advancement in the treatment of strokes caused by large vessel occlusion (LVO), a condition contributing to severe...

Read more

Hemogenyx Pharmaceuticals PLC Announces the Approval and Issuance of U.S. Conditioning Patent

February 2, 2024 2:00 AM

Approval and Issuance of U.S. Conditioning PatentLONDON, UK / ACCESSWIRE / February 2, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that a patent application entitledMethod of Eliminating Hematopoietic Stem Cells/Hematopoietic Progenitors (HSC/HP) In A Patient Using Bi-Specific Antibodieshas been allowed to be issued as a patent by the United States Patent and Trademark Office.Dr Vladislav Sandler, CEO & Co-Founder of...

Read more

AmplifyBio Celebrates Grand Opening of Manufacturing Enablement Center in New Albany, Ohio

February 1, 2024 7:00 AM

NEW ALBANY, OH / ACCESSWIRE / February 1, 2024 / AmplifyBio, a leading commercialization partner for advanced therapies that include cell and gene therapies, proudly announces the successful grand opening of the AmplifyBio Manufacturing Enablement Center (AMEC) in New Albany, Ohio. The milestone event follows the addition of a site dedicated to drug discovery, optimization and characterization work acquired last year in South San Francisco and...

Read more

AltaThera Pharmaceuticals at AF Symposium 2024

January 31, 2024 12:05 PM

AltaThera Pharmaceuticals will present data on Sotalol IV, a treatment that may significantly shorten hospital stays for heart-related illnessesCHICAGO, IL / ACCESSWIRE / January 31, 2024 / AltaThera Pharmaceuticals will be presenting its data at the 29th Annual AF Symposium at the Omni Boston at the Seaport from February 1-3, where company representatives will be available to speak with directly at booth 503. This intensive symposium brings...

Read more

Inherent Biosciences and Genomic Prediction Announce Commercial Partnership to Advance Male Reproductive Health

January 31, 2024 8:38 AM

SALT LAKE CITY, UT / ACCESSWIRE / January 31, 2024 / Inherent Biosciences, Inc. and Genomic Prediction, Inc. (North Brunswick, NJ) are thrilled to announce a comprehensive commercial partnership agreement. This collaboration is set to advance male reproductive health by integrating Inherent Biosciences' groundbreaking Epigenetic Sperm Quality Test (SpermQT™ marketed under the brand Path Fertility) into Genomic Prediction's robust suite of...

Read more

Ensysce Biosciences Announces Positive End of Phase 2 Meeting with FDA for PF614 to Treat Severe Pain

January 31, 2024 8:00 AM

~ PF614 Phase 3 Program Expected to Begin Enrollment in Mid-2024 ~SAN DIEGO, CA / ACCESSWIRE / January 31, 2024 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the completion of a constructive End of Phase 2 meeting with the Food and Drug Administration (FDA) regarding its lead ‘Next Generation' analgesic,...

Read more

Adolore BioTherapeutics to Present at the 5th Annual National Institutes of Health (NIH) HEAL Initiative Scientific Meeting

January 30, 2024 10:00 AM

DELRAY BEACH, FL / ACCESSWIRE / January 30, 2024 / Adolore BioTherapeutics ("Adolore" or the "Company"), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roy C. Levitt, MD, the Company's founder and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at the 5th Annual NIH HEAL...

Read more

Lexaria's Submits Investigational New Drug Application

January 30, 2024 8:45 AM

KELOWNA, BC / ACCESSWIRE / January 30, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that, on January 29, it submitted its much-anticipated Investigational New Drug ("IND") application with the U.S. Food and Drug Administration ("FDA") for its planned U.S. phase 1b hypertension clinical trial HYPER-H23-1 of DehydraTECH-CBD.This IND submission follows a...

Read more